Streetbeat News

Equity Actions

STOK

Stoke Therapeutics announced a proposed public offering of up to $75 million of common stock, leading to an increase in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:49 pm

FDV

KMB

SDG

Kimberly-Clark Corporation (NYSE:KMB) announced a transformation strategy aiming for growth through a new operating model, focusing on 12 brands, and investing in technology. The plan includes reorganizing into three segments, expecting to generate over $3 billion in productivity and $500 million in working capital savings. The transition, to be completed by end of 2024, will incur around $1.5 billion in restructuring costs. The company anticipates organic net sales and adjusted operating profit growth in the mid-to-high single digits, with an adjusted EPS growth in the same range, and at least $2 billion in annual FCF generation. The FY24 outlook remains unchanged, expecting a low-to-mid single digit increase in organic net sales.

Portfolio Pulse from Lekha Gupta

March 27, 2024 | 3:47 pm

DE

Investors have shown a mixed sentiment towards Deere (NYSE:DE), with options trading indicating both bullish and bearish positions. Benzinga's options scanner revealed 24 unusual trades, with a split sentiment of 45% bullish and 54% bearish. The trades focus on a price range between $310.0 and $480.0 for Deere. The largest trades include both calls and puts, with significant amounts invested. Deere, a leading agricultural equipment manufacturer, has seen its stock price increase by 0.47% to $398.9, though it may be overbought according to current RSI values. An analyst from Truist Securities has set a price target of $494.0 for Deere.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:31 pm

OGI

Organigram shares are trading lower following the announcement of pricing for an overnight marketed public offering.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:11 pm

BGNE

Four analysts have recently updated their ratings on BeiGene (NASDAQ:BGNE), showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $219.25, down from $243.33, with ratings adjustments reflecting changes in market conditions and company performance. BeiGene, a biotech firm focused on cancer treatment drugs, has shown a significant revenue growth rate of 66.91% as of December 31, 2023, but struggles with profitability and efficiency metrics like net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

BK

Bank of New York Mellon (NYSE:BK) has seen varied analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target has been raised to $61.75, indicating a bullish outlook from analysts. Key analysts from RBC Capital, Citigroup, Morgan Stanley, and UBS have updated their ratings and price targets, reflecting changes in market conditions and company performance. Despite this, BNY Mellon faces challenges in revenue growth, net margin, ROE, and ROA, compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

ACN

The article provides an in-depth comparison of Accenture (NYSE:ACN) with its competitors in the IT Services industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Accenture is shown to have a higher PE ratio, suggesting potential overvaluation, but a lower PB ratio indicating possible undervaluation. Its PS ratio is high, signaling premium valuation. Compared to industry averages, Accenture has lower profitability and growth potential, with specific metrics like ROE, EBITDA, and gross profit falling behind.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

ABT

Abbott Laboratories (ABT) is analyzed in comparison with its competitors in the Health Care Equipment & Supplies industry. Key financial metrics indicate ABT is undervalued with lower PE, PB, and PS ratios than the industry average. Despite lower ROE suggesting less efficiency in profit generation, ABT shows strong operational performance with high EBITDA and gross profit. However, its revenue growth is significantly lower than the industry average, indicating slower expansion.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

MSFT

A significant portion of investors have taken a bearish stance on Microsoft (NASDAQ:MSFT), with options trading indicating a mix of bullish and bearish expectations. Notably, 35% of trades were bullish, while 64% were bearish. The trading volume and open interest suggest a target price range of $260 to $500 for MSFT. Recent significant trades include both bullish and bearish calls with varying strike prices and sentiments. Microsoft's current stock price is $424.45, with an average analyst price target of $518. Analyst ratings vary, with some downgrades but still positive outlooks.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 2:46 pm

RUN

Sunrun's shares experienced an increase following the announcement that the company will transition from the S&P MidCap 400 to the S&P SmallCap 600.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 2:37 pm